[HTML][HTML] Resistance to BRAF-targeted therapy in melanoma
RJ Sullivan, KT Flaherty - European journal of cancer, 2013 - Elsevier
BRAF mutations are identified in 40–50% of patients with melanoma. Treatment of these
patients with either of two BRAF inhibitors (vemurafenib, dabrafenib) or the MEK inhibitor …
patients with either of two BRAF inhibitors (vemurafenib, dabrafenib) or the MEK inhibitor …
[引用][C] Resistance to BRAF-targeted therapy in melanoma
RJ SULLIVAN, KT FLAHERTY - European journal of cancer …, 2013 - pascal-francis.inist.fr
Resistance to BRAF-targeted therapy in melanoma CNRS Inist Pascal-Francis CNRS
Pascal and Francis Bibliographic Databases Simple search Advanced search Search by …
Pascal and Francis Bibliographic Databases Simple search Advanced search Search by …
Resistance to BRAF-targeted therapy in melanoma
RJ Sullivan, KT Flaherty - European journal of cancer …, 2013 - pubmed.ncbi.nlm.nih.gov
BRAF mutations are identified in 40-50% of patients with melanoma. Treatment of these
patients with either of two BRAF inhibitors (vemurafenib, dabrafenib) or the MEK inhibitor …
patients with either of two BRAF inhibitors (vemurafenib, dabrafenib) or the MEK inhibitor …
Resistance to BRAF-targeted therapy in melanoma.
RJ Sullivan, KT Flaherty - … Journal of Cancer (Oxford, England: 1990 …, 2013 - europepmc.org
BRAF mutations are identified in 40-50% of patients with melanoma. Treatment of these
patients with either of two BRAF inhibitors (vemurafenib, dabrafenib) or the MEK inhibitor …
patients with either of two BRAF inhibitors (vemurafenib, dabrafenib) or the MEK inhibitor …
[引用][C] Resistance to BRAF-targeted therapy in melanoma. Eur J Cancer
RJ Sullivan - (No Title), 2013 - cir.nii.ac.jp
Resistance to BRAF-targeted therapy in melanoma. Eur J Cancer | CiNii Research CiNii
国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データを …
国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データを …
Resistance to BRAF-targeted therapy in melanoma
RJ Sullivan, KT Flaherty - European Journal of Cancer, 2013 - ejcancer.com
BRAF mutations are identified in 40–50% of patients with melanoma. Treatment of these
patients with either of two BRAF inhibitors (vemurafenib, dabrafenib) or the MEK inhibitor …
patients with either of two BRAF inhibitors (vemurafenib, dabrafenib) or the MEK inhibitor …
Resistance to BRAF-targeted therapy in melanoma
RJ Sullivan, KT Flaherty - European Journal of Cancer, 2013 - infona.pl
BRAF mutations are identified in 40–50% of patients with melanoma. Treatment of these
patients with either of two BRAF inhibitors (vemurafenib, dabrafenib) or the MEK inhibitor …
patients with either of two BRAF inhibitors (vemurafenib, dabrafenib) or the MEK inhibitor …
[引用][C] Resistance to BRAF-targeted therapy in melanoma
RJ Sullivan, KT Flaherty - European Journal of Cancer, 2013 - cir.nii.ac.jp
Resistance to BRAF-targeted therapy in melanoma | CiNii Research CiNii 国立情報学研究所
学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データをさがす 大学 …
学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データをさがす 大学 …